“We remain cautiously optimistic that we will have a safe, effective vaccine based on animal studies.” Here is an up-to-date list of COVID-19 trials as discussed at #ACR20 by Dr. A. Fauci @RheumNow https://t.co/DAoLGGtw1A

Fauci: Common endpoints, common parameters provide "bridge" between #COVID19 vaccine trials. "We are cautiously optimistic" for a vaccine "by the end of the calendar year" because of favorable animal studies, though distribution will be later #ACR20 @Rheumnow. https://t.co/vPLEYiGKam

A reminder or the fundamentals to curbing COVID19 per Dr. Anthony Fauci at #ACR20: 1. Everyone needs to wear a mask 2. Maintain 6 feet distance from others 3. Avoid crowds & congregations 4. Outdoor better than indoors 5. Wash your hands frequently @RheumNow @LCalabreseDO https://t.co/khLS7V2A3b

Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug. #RheumTwitter #lupus Abs#0849 #ACR20 @RheumNow https://t.co/8a6OcZmOso

• Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrate…

Valerio et al find 40% of 294 patients w/ #rheumaticdisease refuse or are uncertain about getting inactivated #influenza #vaccine. Key determinants of #vaccinehesitancy found to be concerns about adverse events, safety & efficacy. Abs#0632 #ACR20 @RheumNow https://t.co/f34DAc5WiN

• Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rh…

In the search for biomarkers in PsA, interesting study showing absolute lymphocyte count is negatively correlated with cardiovascular disease risk score and red cell distribution width and increases with TNF-Inhibitor Therapy @rheumnow #ACR20 Abstr#878

Some great abstracts on #vaccine hesitancy in the #infection in #rheumaticdiseases poster session! What's the greatest concern for patients offered #influenza & #pneumococcal vaccines? How can we address these concerns & encourage vaccine uptake? Comment below! #ACR20 @RheumNow

Tracking CRP in the hyper-acute phase of admission for #COVID19 predictive of progression to critical illness- suggests trends of inflammatory biomarkers, not absolute admission values, may be most useful for triage & therapy. Abs#0626 #ACR20 @RheumNow https://t.co/E14y3e4ALi

• Early Rise in CRP Is Associated with Progression to Respiratory Failure and Int…

Patients with ARDs have incr. susceptibility to #infection. Real-world study shows suboptimal #influenza, #pneumococcal & #herpeszoster #vaccination coverage in these patients. Important to consider strategies to improve uptake. Abs#0541 #ACR20 @RheumNow https://t.co/GAapkzILvW

• Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster …

Dr Rubin of @NEJM on #vaccine development: safety and efficacy very important. Great keynote lecture! @RheumNow #ACR20 https://t.co/hVR2rmOMNp

Inflammation is not a single entity, and the imperative to dissect it carefully is so great in irAEs - in both treatment and measurement. "I'm attempting to stir the pot" - @LCalabreseDO - and there really is plenty to think about. https://t.co/8C6RbMI2l9

One of my #ACR20 highlights about to start - irAE Study Group, hosted by @CCalabreseDO & @NohaMDAnderson Imminent paradigm definition by @LCalabreseDO: one of the biggest challenges in the field: how to target therapies in irAEs, to maintain cancer response #ACR2020 @RheumNow https://t.co/WzFbCc8TuT

Dr. Siri will see you now...🤖 Machine learning identified 9 signatures including nail pso, CRP and 7 biomarkers to distinguish PsA from PsO pts without arthritis and will help diagnose PsA early. ➡️will need to test independent data @RheumNow #ACR20 Abs#0502

@LCalabreseDO @cappelliMD @MarieKostine @EladSharonMD @rheum_covid For those who missed it, my attempt to capture some of it in a Twitter thread: https://t.co/Z55sV7ZyBt

• https://twitter.com/drdavidliew/status/1324774515386114050